ArticleDisease models & mechanisms2016
A rat model for hepatitis E virus.
Article in Disease models & mechanisms, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Molnupiravir is effective against hepatitis E virus infection in an animal model.Hepatology communications · 2026Article
- Rocahepevirus ratti: molecular evolution, zoonotic potential and public health impact.Nature communications · 2026Review
- Proliferative Cell Targeting and Epithelial Cell Turnover Fuels Hepatitis E Virus Replication in Human Intestinal Enteroids.Gastro hep advances · 2026Article
- Spillover of Rat Hepatitis E Virus into Humans: An Emerging Zoonosis?Future virology · 2025Article
- Research Progress on Hepatitis E Virus Culture.Pathogens (Basel, Switzerland) · 2025Review
- Cell binding tropism of rat hepatitis E virus is a pivotal determinant of its zoonotic transmission to humans.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- The question of screening organ donors for hepatitis e virus: a case report of transmission by kidney transplantation in France and a review of the literature.Virology journal · 2024Review
- Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms.Viruses · 2023Review
- Expanding the Hepatitis E Virus Toolbox: Selectable Replicons and Recombinant Reporter Genomes.Viruses · 2023Review
- 3D engineered tissue models for studying human-specific infectious viral diseases.Bioactive materials · 2023Review
- A small animal model of chronic hepatitis E infection using immunocompromised rats.JHEP reports : innovation in hepatology · 2022Article
- HuH-7-Lunet BLR Cells Propagate Rat Hepatitis E Virus (HEV) in a Cell Culture System Optimized for HEV.Viruses · 2022Article
- Revisiting the Mongolian Gerbil Model for Hepatitis E Virus by Reverse Genetics.Microbiology spectrum · 2022Article
- Viral Hepatitis E and Chronicity: A Growing Public Health Concern.Frontiers in microbiology · 2020Review
- First detection of Hepatitis E virus (Orthohepevirus C) in wild brown rats (Rattus norvegicus) from Great Britain.Zoonoses and public health · 2019Article
- Small Animal Models of Hepatitis E Virus Infection.Cold Spring Harbor perspectives in medicine · 2019Review
- Cell Culture Models for Hepatitis E Virus.Viruses · 2019Review
- Animal Models for Hepatitis E virus.Viruses · 2019Review
- Liver-specific Gene Delivery Using Engineered Virus-Like Particles of Hepatitis E Virus.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) is one of the prime causes of acute viral hepatitis, and chronic hepatitis E is increasingly recognized as an important problem in the transplant setting. Nevertheless, the fundamental understanding of the biology of HEV replication is limited and there are few therapeutic options. The development of such therapies is partially hindered by the lack of a robust and convenient animal model. We propose the infection of athymic nude rats with the rat HEV strain LA-B350 as such a model. A cDNA clone, pLA-B350, was constructed and the infectivity of its capped RNA transcripts was confirmed in vitro and in vivo Furthermore, a subgenomic replicon, pLA-B350/luc, was constructed and validated for in vitro antiviral studies. Interestingly, rat HEV proved to be less sensitive to the antiviral activity of α-interferon, ribavirin and mycophenolic acid than genotype 3 HEV (a strain that infects humans). As a proof-of-concept, part of the C-terminal polymerase sequence of pLA-B350/luc was swapped with its genotype 3 HEV counterpart: the resulting chimeric replicon replicated with comparable efficiency as the wild-type construct, confirming that LA-B350 strain is amenable to humanization (replacement of certain sequences or motifs by their counterparts from human HEV strains). Finally, ribavirin effectively inhibited LA-B350 replication in athymic nude rats, confirming the suitability of the rat model for antiviral studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.